Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedNov 29, 2022
DataAggregated Company Financials
Companies32
  • 7D4.1%
  • 3M12.1%
  • 1Y-32.3%
  • YTD-29.8%

The Biotech industry is up 4.1% in the last week, with Scancell Holdings up 27%. Meanwhile, Genus actually underperformed within the industry, shrinking 6.6% in the last week. In the past year, the industry is down 32%. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 30 Nov 2022UKĀ£8.1bUKĀ£1.2b-UKĀ£139,491,980.0024.4x-58x7x
Fri, 28 Oct 2022UKĀ£7.3bUKĀ£1.2b-UKĀ£148,574,600.0022.9x-48.9x6.3x
Sun, 25 Sep 2022UKĀ£7.2bUKĀ£1.2b-UKĀ£174,838,754.0026.4x-41.3x6.2x
Tue, 23 Aug 2022UKĀ£7.5bUKĀ£1.1b-UKĀ£203,421,153.0036.6x-36.7x6.7x
Thu, 21 Jul 2022UKĀ£7.0bUKĀ£1.1b-UKĀ£202,133,604.0035.2x-34.5x6.3x
Sat, 18 Jun 2022UKĀ£6.6bUKĀ£1.1b-UKĀ£159,017,173.0036.1x-41.8x6x
Mon, 16 May 2022UKĀ£6.9bUKĀ£1.1b-UKĀ£146,427,737.0036.6x-47.1x6.2x
Wed, 13 Apr 2022UKĀ£7.6bUKĀ£1.1b-UKĀ£91,924,862.0040.5x-82.5x7x
Fri, 11 Mar 2022UKĀ£7.5bUKĀ£1.1b-UKĀ£134,929,617.0031.9x-55.6x6.9x
Sun, 06 Feb 2022UKĀ£8.9bUKĀ£1.1b-UKĀ£119,969,127.0038.6x-74.3x8.2x
Tue, 04 Jan 2022UKĀ£11.5bUKĀ£1.1b-UKĀ£120,793,971.0057.3x-94.9x10.6x
Thu, 02 Dec 2021UKĀ£11.2bUKĀ£1.1b-UKĀ£121,397,789.0061.4x-92.2x10.3x
Sat, 30 Oct 2021UKĀ£11.7bUKĀ£1.1b-UKĀ£136,297,738.0070.8x-86x10.8x
Mon, 27 Sep 2021UKĀ£12.3bUKĀ£1.1b-UKĀ£127,246,067.0069.7x-96.3x11.1x
Wed, 25 Aug 2021UKĀ£12.5bUKĀ£1.0b-UKĀ£172,541,949.9131.1x-72.4x12.2x
Thu, 01 Jul 2021UKĀ£11.2bUKĀ£1.0b-UKĀ£172,541,949.9130.1x-65x11x
Sun, 04 Apr 2021UKĀ£10.8bUKĀ£1.0b-UKĀ£166,311,048.5231.3x-65x10.6x
Wed, 06 Jan 2021UKĀ£9.7bUKĀ£1.0b-UKĀ£143,856,708.8133.2x-67.1x9.6x
Sat, 10 Oct 2020UKĀ£8.1bUKĀ£985.1m-UKĀ£118,992,987.8156.2x-68.1x8.2x
Fri, 03 Jul 2020UKĀ£7.5bUKĀ£992.9m-UKĀ£137,441,757.4556.4x-54.9x7.6x
Mon, 06 Apr 2020UKĀ£6.2bUKĀ£985.7m-UKĀ£113,867,379.8153.2x-54.1x6.2x
Thu, 09 Jan 2020UKĀ£6.3bUKĀ£946.8m-UKĀ£64,026,720.4453.1x-98.9x6.7x
Price to Earnings Ratio

-75.7x


Total Market Cap: UKĀ£6.4bTotal Earnings: -UKĀ£84,370,311.30Total Revenue: UKĀ£925.4mTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -72.4x202020212022
Current Industry PE
  • Investors are pessimistic on the British Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 7.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 7.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.10%
Healthcare0.038%
Biotech4.06%
Biotech4.06%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SCLP Scancell HoldingsUKĀ£0.2327.4%
+UKĀ£40.8m
14.8%PB10.5x
FARN Faron Pharmaceuticals OyUKĀ£2.7323.9%
+UKĀ£31.4m
-12.1%PE-7.9x
PRTC PureTech HealthUKĀ£2.722.8%
+UKĀ£20.9m
-7.0%PS48.7x
AVCT Avacta GroupUKĀ£1.175.7%
+UKĀ£16.3m
0.9%PS43.7x
OXB Oxford BiomedicaUKĀ£3.703.6%
+UKĀ£12.5m
-71.9%PS2.8x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

OXB

UKĀ£3.70

Oxford Biomedica

7D

3.6%

1Y

-71.9%

HEMO

UKĀ£0.013

Hemogenyx Pharmaceuticals

7D

-5.3%

1Y

-27.2%

SNG

UKĀ£0.20

Synairgen

7D

9.8%

1Y

-90.4%

SCLP

UKĀ£0.23

Scancell Holdings

7D

27.4%

1Y

14.8%

RENE

UKĀ£0.23

ReNeuron Group

7D

-6.0%

1Y

-75.3%

NIOX

UKĀ£0.36

NIOX Group

7D

2.5%

1Y

-3.4%

ETX

UKĀ£0.22

e-therapeutics

7D

10.4%

1Y

-45.0%

DEST

UKĀ£0.31

Destiny Pharma

7D

-3.8%

1Y

-73.2%

BVXP

UKĀ£36.00

Bioventix

7D

-1.4%

1Y

9.1%

AVCT

UKĀ£1.17

Avacta Group

7D

5.7%

1Y

0.9%

FARN

UKĀ£2.73

Faron Pharmaceuticals Oy

7D

23.9%

1Y

-12.1%

ABC

UKĀ£12.54

Abcam

7D

-4.2%

1Y

-26.5%

PRTC

UKĀ£2.72

PureTech Health

7D

2.8%

1Y

-7.0%